Despite extensive exploration in preclinical and clinical trials for cervical and breast tumors, CAR T-cell-based immunotherapy has struggled to replicate the success observed with CD19.CAR T cells in hematopoietic malignancies (5, 39). Here, CD19 is linked to breast neoplasm.